A Planned Phase III Trial of Neratinib Plus Temsirolimus for Patients With Metastatic HER2-Breast Cancer.

Trial Profile

A Planned Phase III Trial of Neratinib Plus Temsirolimus for Patients With Metastatic HER2-Breast Cancer.

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2015

At a glance

  • Drugs Neratinib (Primary) ; Temsirolimus
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Puma Biotechnology
  • Most Recent Events

    • 02 Mar 2015 According to Puma Biotechnology, Inc. media release, company is planning to initiate this trial in the second half of 2015.
    • 02 Mar 2015 Planned initiation date changed from 1 Dec 2014 to 1 Jul 2015, as reported by Puma Biotechnology, Inc. media release.
    • 13 Nov 2013 Planned initiation date changed from 1 Dec 2013 to 1 Jun 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top